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Background: Cryptogenic hepatocellular carcinoma (HCC) is thought to arise due to non-alcoholic fatty liver
disease (NAFLD). This study investigated the prevalence, clinical features, and outcomes of cryptogenic HCC and
compared them with those of HCC related to hepatitis B virus infection (HBV-HCC), hepatitis C virus infection
(HCV-HCC), and alcohol (ALC-HCC) in Korea.
Methods: The clinical features, treatment modalities, and survival data for 480 patients with HCC consecutively
enrolled from January 2003 to June 2012 were analyzed. Computed tomography images were used to measure
the visceral fat area (VFA) and liver-spleen density ratio.
Results: Cryptogenic HCC accounted for 6.8% of all HCC cases, whereas HBV-HCC, HCV-HCC, and ALC-HCC
accounted for 62.7%, 13.5%, and 10.7% of HCC cases, respectively. The cryptogenic HCC group was characterized
by older age, a low proportion of male patients, a high proportion of patients with metabolic syndrome or single
nodular presentation, and a low proportion of patients with portal vein invasion compared to the viral-HCC and
ALC-HCC groups. However, Child Pugh classes, tumor stages, and overall survival rates of cryptogenic HCC patients
were similar to those of patients with HCC of other etiologies. VFA in cryptogenic HCC patients was significantly
higher than that in viral-HCC patients, but similar to that in ALC-HCC patients. The liver-spleen density ratio did not
vary according to HCC etiology.
Conclusions: Cryptogenic HCC accounts for approximately 7% of HCC cases in Korea, associated with an older age
at diagnosis, more frequent occurrence of metabolic syndrome, and less aggressive tumor characteristics, but
similar survival compared to viral-HCC or ALC-HCC. Based on VFA and the liver-to-spleen density ratio, cryptogenic
HCC may be burnt-out NAFLD in which visceral fat remains but liver fat is depleted.
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Hepatocellular carcinoma (HCC) is the fifth most preva-
lent cancer and the third most common cause of cancer
mortality in the world [1]. The major underlying cause
of HCC in many Asian countries is hepatitis B virus
(HBV) infection, followed by hepatitis C virus (HCV)
infection and alcohol [2]. However, non-alcoholic fatty* Correspondence: jsh@snubh.org
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reproduction in any medium, provided the orliver disease (NAFLD) including non-alcoholic steato-
hepatitis (NASH) increasingly appears to be a cause of
HCC because of the recent global epidemic of obesity
[3]. NASH can progress to cirrhosis and HCC, and a
greater cause for alarm is that HCC can develop in the
absence of cirrhosis when NAFLD is present [4,5]. Until
now, there has been insufficient evidence to guide the
surveillance examinations for early detection of HCC in
the NAFLD population.
NAFLD accounts for approximately 13% of all HCC
cases in the United States [6] and for 2% of cases in Japan
[7]. However, once cirrhosis develops during the course of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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steatosis and inflammation often disappear, and the eti-
ology becomes difficult to evaluate even on pathologic
examination of the liver tissue. Therefore, on exclusion
of HBV, HCV, alcohol, and other known etiologies such
as autoimmune liver diseases or genetic liver diseases,
most cases of cryptogenic cirrhosis are considered to
be caused by burnt-out NASH [8]. Consequently, the
clinical characteristics of cryptogenic HCC can differ
from those of other HCCs that have arisen from viral
or alcoholic liver disease.
In a recent study, the severity of fatty liver was positively
related to visceral fat area (VFA) and the liver-to-spleen
density ratio assessed by computed tomography (CT)
[9], and xenon CT can be used to measure hepatic fat
deposition in NASH patients [10]. However, because
VFA and the liver-to-spleen ratio have not been studied
in HCC patients until now, we undertook a comparative
analysis of VFA and the liver-to-spleen density ratio
according to different HCC etiologies.
The aim of present study was to investigate the preva-
lence, characteristics, and outcomes of cryptogenic HCC
and to compare them with those of HBV-associated HCC
(HBV-HCC), HCV-associated HCC (HCV-HCC), and
alcohol-associated HCC (ALC-HCC).Methods
Subjects and etiologic classification of HCC
The subjects were 512 patients consecutively diagnosed
with HCC in Seoul National University Bundang Hospital
from January 2003 to June 2012. The diagnosis of HCC
was based on histology or typical radiographic findings,
which are hepatic nodules with arterial enhancement and
venous wash-out on contrast-enhanced CT or magnetic
resonance imaging (MRI) [11,12].
HCC was classified etiologically as HBV-HCC (hepatitis
B surface antigen, HBsAg positivity), HCV-HCC (anti-
HCV positivity), ALC-HCC (intake of more than 40 g/day
of alcohol for men and 20 g/day for women for more than
10 years) [3], and cryptogenic HCC. Cryptogenic HCC
diagnosis was an exclusion diagnosis according to the
criteria for NAFLD [6], which was based on the following:
(1) absence of serologic or clinical evidence of HBV or
HCV infection; (2) alcohol consumption < 20 g/day in
men (< 10 g/day in women); and (3) no evidence of other
causes of chronic liver disease such as autoimmune hepa-
titis, drug-induced hepatitis, hemochromatosis, Wilson’s
disease, intestinal bypass surgery, Budd-Chiari syndrome,
primary biliary cirrhosis, and primary sclerosing cholan-
gitis. We excluded 32 patients with combined etiologies,
Budd-Chiari syndrome, or autoimmune hepatitis and
the remaining 480 patients were finally enrolled in
this study.Comparative analyses of clinical variables, treatment
modalities, and survival data of cryptogenic HCC
Retrospective analyses of demographic data, comorbid
conditions, clinical and pathological data, tumor char-
acteristics on radiologic images, treatment modalities,
and survival rates were performed, comparing crypto-
genic HCC with HBV-HCC, HCV-HCC, or ALC-HCC.
This study was approved by the Institutional Review
Board of the Seoul National University Bundang Hospital.
Clinical data on height; weight; body mass index (BMI);
hypertension; diabetes; hyperlipidemia; HBsAg positivity;
anti-HBsAg positivity; anti-HCV positivity; levels of trigly-
ceride (TG), total cholesterol, low-density lipoprotein
cholesterol (LDL), high-density lipoprotein cholesterol
(HDL), total protein, serum albumin, alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), γ glutamyl
transferase, and alkaline phosphatase (ALP); platelet count,
hemoglobin levels, serum sodium levels, creatinine levels,
and alpha-fetoprotein (AFP) levels were retrieved from
electronic records, and the Child-Pugh class and model
for end-stage liver disease (MELD) score were calculated.
Obesity was defined as a BMI of ≥25 kg/m2 according to
the criterion of the World Health Organization and the
National Institute of Health for obesity in Asian popula-
tions [13].
To analyze tumor characteristics, the number and diam-
eter of HCC nodules, the presence of vascular invasion,
tumor stage represented as Barcelona Clinic Liver Cancer
(BCLC) and TNM stages [14,15], and presence of accom-
panying cirrhosis in the non-tumorous liver were evalu-
ated. Liver cirrhosis was defined by the presence of
portal hypertension manifested as varices, splenomeg-
aly, ascites, or hepatic encephalopathy and compatible
imaging findings accompanied by throm-bocytopenia
(<100,000/μl) [11].
Treatment modalities for HCC were classified as surgi-
cal resection, transarterial chemoembolization (TACE),
radiofrequency ablation (RFA), percutaneous ethanol
injection (PEI), systemic chemotherapy, targeted agent
(sorafenib), and liver transplantation during the follow-
up period. Overall survival of the cryptogenic HCC
patients was compared with that of viral or alcoholic
HCC patients.
Measurement of visceral fat area and the liver-to-spleen
density ratio on CT images
To investigate the association between NAFLD and
cryptogenic HCC, VFA and the liver-to-spleen density
ratio were measured in 113 patients by analyzing CT
images obtained at the level of the umbilicus using
commercially available software (Rapidia 2.8; INFINITT,
Seoul, Korea). VFA was defined as the sum of intraperi-
toneal fat area with attenuation between -250 and -50
Hounsfield units (HU) on a pre-enhanced liver CT scan.
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interest (ROIs) of 100 mm2 in segments 5, 6, 7, and 8 of
the liver and spleen attenuations were measured as the
mean HU of 2 ROI values in the spleen. Using these
values, we determined the liver-to-spleen density ratio.
ROIs in the liver and spleen were selected in peripheral
areas away from major vessels and tumors. VFA and the
liver-to-spleen density ratio were compared between 18
cryptogenic HCC patients and 36 randomly selected
age- and sex-matched HBV-HCC patients or 36 randomly
selected age- and sex-matched HCV-HCC patients. How-
ever, because the 23 ALC-HCC patients with available
VFA data were mostly male, sex matching was not pos-
sible. Further, accurate age- and sex-matching was not
possible because of the small sample size of each subgroup
of HCC patients.
Statistical analysis
For comparative analysis, the Mann-Whitney test was
used for quantitative variables and the chi-square test
or 2-tailed Fischer’s exact test was used for qualitative
variables. Overall survival and disease free survival
according to HCC etiology were compared using the
Kaplan-Meier model and log-rank test. A significant
p value was defined as < 0.05 and all statistical analyses
were performed using PASW software (Version 18,
SPSS Inc, Chicago, IL, USA).
Results
The prevalence of cryptogenic HCC in Korea
Of the 512 HCC cases, HBV-HCC accounted for 321
(62.7%), HCV-HCC accounted for 69 (13.5%), ALC-
HCC accounted for 55 (10.7%), and cryptogenic HCC
accounted for 35 (6.8%) (Figure 1). Of 35 patients with
cryptogenic HCC, 14 were asymptomatic and were diag-
nosed during a health check-up, 10 patients with liverFigure 1 The prevalence of cryptogenic hepatocellular carcinoma (HC
(HBV) infection followed by hepatitis C virus (HCV) infection and alcohol (Acirrhosis were diagnosed during a surveillance examin-
ation, and the remaining 11 patients (31.4%) presented
with symptoms such as abdominal pain (n = 8), a palp-
able mass (n = 2) or weight loss (n = 1) (Figure 2).Clinical features of cryptogenic HCC compared to HCC
caused by other etiologies
The clinical characteristics of HCC according to eti-
ology are summarized in Table 1. Cryptogenic HCC
was diagnosed at a significantly older age (68.3 ± 10.5
years) than HBV-HCC (57.1 ± 10.3 years, p < 0.001) and
a significantly lower proportion of patients were male
(57.1%) compared to ALC-HCC (92.7%, p < 0.001) or
HBV-HCC (76.0%, p = 0.015) patients. Twenty-six pa-
tients (74.3%) with cryptogenic HCC had one or more
components of metabolic syndrome, showing a higher
prevalence of obesity (45.7%), diabetes (37.1%), hyper-
tension (57.1%), and hyperlipidemia (25.7%) compared
to patients with other etiologies. Although serum
hemoglobin levels were significantly lower in crypto-
genic HCC patients than in HBV-HCC patients and
serum creatinine levels were significantly lower in
cryptogenic HCC patients than HCV-HCC patients,
whereas other laboratory tests and liver function as
assessed by Child-Pugh class and the MELD score did
not differ significantly according to HCC etiology.
Tumor characteristics and stage for cryptogenic HCC
are summarized in Table 2. Cryptogenic HCC pre-
sented as a solitary nodule more frequently (74.3%)
than HBV-HCC (53.3%, p = 0.026), HCV-HCC (49.3%,
p = 0.020), and ALC-HCC (36.4%, p = 0.002). Moreover,
it presented with a significantly lower rate of portal
vein thrombosis (11.4%) than HBV-HCC (27.7%, p =
0.037) and HCV-HCC (31.9%, p = 0.023). However, no
significant differences were noted in tumor stage inC). The major underlying cause of HCC in Korea is hepatitis B virus
LC). Cryptogenic HCC accounts for 6.8% of HCC cases.
Figure 2 Initial presentation at diagnosis of hepatocellular carcinoma (HCC) in 35 patients with cryptogenic HCC. Of these, only 11
patients presented with symptoms such as abdominal pain, palpable mass, and weight loss.
Table 1 Comparison of demographic data, comorbidities, and laboratory data between cryptogenic hepatocellular
carcinoma (HCC) patients and patients with HCC associated with hepatitis B virus infection, hepatitis C virus infection,
and alcohol
Cryptogenic
HCC (n = 35)
HBV-HCC * p HCV-HCC **p ALC-HCC ***p
(n = 321) (n = 69) (n = 55)
Age, yr† 68.3 ± 10.5 57.1 ± 10.3 <0.001 68.1 ± 9.0 0.896 65.5 ± 10.0 0.164
Gender, Male†† 20 (57.1) 244 (76.0) 0.015 44 (63.8) 0.512 51 (92.7) <0.001
BMI (kg/m2) † 24.6 ± 3.3 23.4 ± 3.4 0.034 22.2 ± 3.9 0.002 24.0 ± 4.3 0.143
Obesity†† 16 (45.7) 85 (26.7) 0.018 13 (18.8) 0.004 12 (21.8) 0.017
Diabetes †† 13 (37.1) 55 (17.1) 0.004 17 (24.6) 0.183 19 (34.5) 0.802
Hypertension †† 20 (57.1) 77 (24.0) <0.001 32 (46.4) 0.299 18 (32.7) 0.022
Hyperlipidemia†† 9 (25.7) 10 (3.1) <0.001 4 (5.8) 0.004 2 (3.6) 0.003
Follow-up period, mo† 26.1 ± 27.8 28.5 ± 27.0 0.573 29.9 ± 25.1 0.362 29.2 ± 25.6 0.518
Albumin (g/dL) † 3.7 ± 0.5 3.8 ± 0.6 0.346 3.7 ± 0.6 0.780 3.7 ± 0.5 0.545
Bilirubin (mg/dL) † 1.2 ± 0.7 1.6 ± 2.4 0.437 1.8 ± 2.7 0.551 1.6 ± 1.9 0.216
ALP (IU/L) † 123.3 ± 73.3 137.2 ± 97.2 0.555 125.2 ± 63.1 0.728 132.6 ± 91.8 0.855
AST (IU/L) † 83.8 ± 165.4 89.3 ± 140.5 0.342 111.9 ± 114.6 <0.001 53.2 ± 31.9 0.419
ALT (IU/L) † 58.7 ± 99.0 64.4 ± 98.4 0.111 78.6 ± 60.6 0.001 47.4 ± 72.7 0.371
Platelet (103/μL) †† (<10/10 ~ 13/>13) 5/7/23 87/50/182 0.157 19/18/32 0.056 14/9/42 0.263
PT-INR† 1.14 ± 0.16 1.15 ± 0.18 0.897 1.15 ± 0.14 0.791 1.14 ± 0.19 0.593
Hemoglobin (g/dL) † 12.6 ± 2.3 13.6 ± 2.0 0.007 12.8 ± 2.1 0.570 13.1 ± 2.2 0.460
Na (mmol/L) † 137.0 ± 8.8 137.4 ± 9.6 0.551 137.7 ± 4.0 0.535 137.9 ± 3.4 0.340
Creatinine (mg/dL) † 0.9 ± 0.2 1.0 ± 0.3 0.738 1.2 ± 1.0 0.040 1.2 ± 1.0 0.537
C-P class (A/BC) †† 29/6 246/75 0.404 50/19 0.241 40/15 0.268
MELD score† 9.0 ± 2.9 9.6 ± 3.2 0.273 10.2 ± 3.7 0.076 10.5 ± 4.3 0.051
†Expressed as the mean ± standard deviation. ††Expressed as the number of subjects (%).
Values in bold, statistically significant (p < 0.05).
BMI, Body mass index; AST, Aspartate transaminase; ALT, Alanine transaminase; PT-INR, Prothrombin time-international normalized ratio; C-P class, Child-Pugh class;
MELD, Model for end-stage liver disease; HBV-HCC, Hepatitis B-associated hepatocellular carcinoma; HCV-HCC, Hepatitis C-associated hepatocellular carcinoma;
ALC-HCC, Alcohol-associated hepatocellular carcinoma.
*p: Cryptogenic HCC vs. HBV-HCC.
**p: Cryptogenic HCC vs. HCV-HCC.
***p: Cryptogenic HCC vs. ALC-HCC.
Lee et al. BMC Cancer 2013, 13:335 Page 4 of 9
http://www.biomedcentral.com/1471-2407/13/335
Table 2 Comparison of tumor characteristics and treatment modalities between cryptogenic hepatocellular carcinoma
(HCC) patients and patients with HCC associated with hepatitis B virus infection, hepatitis C virus infection,
and alcohol
Cryptogenic
HCC (n = 35)
HBV-HCC * p HCV-HCC **p ALC-HCC ***p
(n = 321) (n = 69) (n = 55)
AFP (IU/mL) 0.036 0.938 0.116
<20 19 (57.6) 108 (34.4) 33 (53.2) 35 (70.0)
20 ~ 200 4 (12.1) 78 (24.8) 12 (19.4) 8 (16.0)
>200 10 (30.3) 128 (40.8) 17 (27.4) 7 (14.0)
PVT 4 (11.4) 89 (27.7) 0.037 22 (31.9) 0.023 10 (18.2) 0.389
Extrahepatic metastasis 1 (2.9) 19 (5.9) 0.706 5 (7.2) 0.661 3 (5.5) 0.560
TNM stage 0.361 0.889 0.385
I 16 (45.7) 121 (37.7) 34 (49.3) 15 (27.3)
II 5 (14.3) 57 (17.8) 10 (14.5) 20 (36.4)
III 13 (37.1) 122 (38.0) 20 (29.0) 17 (30.9)
IV 1 (2.9) 21 (6.5) 5 (7.2) 3 (5.5)
BCLC stage 0.120 0.380 0.120
A 18 (51.4) 148 (46.1) 38 (55.1) 23 (41.8)
B 11 (31.4) 65 (20.2) 8 (11.6) 15 (27.3)
C 6 (17.1) 94 (29.3) 20 (29.0) 13 (23.6)
D 0 (0) 14 (4.4) 3 (4.3) 4 (7.3)
HCC nodules 0.026 0.020 0.002
1 26 (74.3) 171 (53.3) 34 (49.3) 20 (36.4)
2 ~ 3 4 (11.4) 63 (19.6) 14 (20.3) 17 (30.9)
≥4 5 (14.3) 87 (27.1) 21 (30.4) 18 (32.7)
Largest tumor size 0.536 0.517 0.940
<2cm 10 (28.6) 73 (22.7) 27 (39.1) 15 (27.3)
2 ~ 5cm 12 (34.3) 120 (37.4) 17 (24.6) 21 (38.2)
>5cm 13 (37.1) 128 (39.9) 25 (36.2) 19 (34.5)
Treatment modality
Resection 4 (11.4) 45 (14.0) 0.801 7 (10.1) 0.841 8 (14.5) 0.672
RFA 9 (25.7) 111 (34.6) 0.349 28 (40.6) 0.135 15 (27.3) 0.871
TACE 28 (80.0) 262 (81.6) 0.820 54 (78.3) 0.837 46 (83.6) 0.660
PEI 1 (2.9) 10 (3.1) 1.000 2 (2.9) 1.000 1 (1.8) 1.000
Systemic chemotherapy 2 (5.7) 24 (7.5) 1.000 1 (1.4) 0.261 3 (5.3) 1.000
Sorafenib 3 (8.6) 25 (7.8) 0.747 7 (10.1) 1.000 6 (10.9) 0.719
Liver transplantation 0 (0.0) 6 (1.9%) 1.000 0 (0.0) 1 (1.8%) 1.000
No treatment 2 (5.7) 35 (10.4) 0.558 7 (10.1) 0.714 7 (12.7) 0.473
Data are expressed as the number (%). Values in bold, statistically significant (p < 0.05).
AFP, Alpha-fetoprotein; PVT, Portal vein thrombosis; BCLC, Barcelona Clinic Liver Cancer; HCC, Hepatocellular carcinoma; RFA, Radiofrequency ablation; TACE,
Transarterial chemoembolization; PEI, Percutaneous ethanol injection; HBV-HCC, Hepatitis B-associated hepatocellular carcinoma; HCV-HCC, Hepatitis C-associated
hepatocellular carcinoma; ALC-HCC, Alcohol-associated hepatocellular carcinoma.
*p: Cryptogenic HCC vs. HBV-HCC.
**p: Cryptogenic HCC vs. HCV-HCC.
***p: Cryptogenic HCC vs. ALC-HCC.
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HCC and other HCCs.
Of 35 patients with cryptogenic HCC, 27 (77.1%) had
liver cirrhosis according to clinical or image findings.No significant differences were noted in age, sex,
BMI, tumor size, and number of nodules between 8
non-cirrhotic HCC patients and 27 cirrhotic patients
(Table 3).
Table 3 Demographics and tumor characteristics for
cryptogenic hepatocellular carcinoma patients stratified
by the presence of liver cirrhosis
No cirrhosis (n = 8) Cirrhosis (n = 27) p
Age (yr) † 60.8 ± 16.8 70.5 ± 6.7 0.080
Gender, male†† 7 (87.5) 13 (48.1) 0.101
BMI (kg/m2) † 23.0 ± 1.9 25.1 ± 3.5 0.104
HCC nodules 0.080
1 8 18
2 ~ 3 0 4
≥4 0 5
Largest tumor size 0.518
<2cm 3 7
2 ~ 5cm 0 12
>5cm 5 8
PVT†† 0 (0) 4 (14.8) 0.553
†Expressed as the mean ± standard deviation. ††Expressed as the number of
subjects (%).
BMI, Body mass index; HCC, Hepatocellular carcinoma; PVT, Portal
vein thrombosis.
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No differences were noted in treatment modalities be-
tween cryptogenic HCC and other HCC patients (Table 2).
Comparative analyses of overall survival showed no sig-
nificant differences between cryptogenic HCC and HCC
patients with other etiologies (Figure 3). Causes of death
in cryptogenic HCC patients were hepatic failure (n = 8)
and HCC progression (n = 4), and none of the cryptogenic
HCC patients died due to a cardiovascular event. In
addition, disease free survival defined as the duration from
date of curative-intent treatment to date of local and/or
distant recurrence or death of 187 patients who under-
went curative treatment was obtained, which showed no
significant differences between cryptogenic HCC patientsFigure 3 Overall survival time of hepatocellular carcinoma (HCC) pati
of the 35 cryptogenic HCC patients with that of 321 hepatitis B virus-assoc
(HCV-HCC) patients (B), and 55 alcohol-associated HCC (ALC-HCC) patients(n = 15) and HBV-HCC (n = 128), HCV-HCC (n = 29),
and ALC-HCC (n = 15) (Figure 4).
Measurement of VFA and the liver-to-spleen density ratio
VFA and the liver-to-spleen density ratio were mea-
sured in 18 patients with cryptogenic HCC who were
age- and sex-matched with 36 HBV-HCC patients and
36 HCV-HCC patients (Table 4). The cryptogenic HCC
patients showed significantly higher VFA (134.4 ± 53.9
cm2) than the HBV-HCC (100.0 ± 51.3 cm2, p = 0.037)
and HCV-HCC (105.0 ± 51.1 cm2, p = 0.034) patients,
whereas VFA did not differ between cryptogenic HCC
and ALC-HCC patients. In contrast, the liver-to-spleen
density ratio did not differ between the cryptogenic
HCC patients and the HBV-HCC, HCV-HCC, and
ALC-HCC patients.
Discussion
Cryptogenic HCC accounted for 6.8% of HCC cases in
this study. Compared to HCC of other etiologies, the
clinical features and outcomes associated with crypto-
genic HCC were older age, accompanying metabolic
syndrome, single nodules, and less portal vein invasion,
although Child Pugh classes, tumor stages, and overall
cumulative survival rates did not differ significantly.
Interestingly, VFA and the liver-to-spleen density ratio
measurements supported the theory that cryptogenic
HCC may be burnt-out NAFLD with residual visceral
fat but with depleted liver fat.
The prevalence of NAFLD is approximately 18% in
Korea [16,17], with a rapidly increasing tendency as in
Western countries. NAFLD is considered an important
etiology of HCC since Powell et al. reported the first
case of NAFLD-associated HCC (NAFLD-HCC) [18,19],
although a recent systematic review showed that the risk
for HCC was substantially lower for NASH cirrhosisents according to etiology. Comparisons of the cumulative survival
iated HCC (HBV-HCC) patients (A), 69 hepatitis C virus-associated HCC
(C) are shown.
Figure 4 Disease free survival of hepatocellular carcinoma (HCC) patients according to etiology. There were no significant differences in
disease free survival between cryptogenic HCC patients (n = 15) and patients with HCC associated with hepatitis B virus infection (A, n = 128),
hepatitis C virus infection (B, n = 29), and alcohol (C, n = 15).
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that cryptogenic HCC accounted for 6.8% of current
HCC cases in Korea, a prevalence lower than that in the
United States (13%) [6], but similar to that in Japan
(7.1%) and Italy (7%) [7,21]. However, the true preva-
lence of NAFLD-HCC is difficult to evaluate because
liver fat storage is depleted as hepatic fibrosis progresses,
a process known as burnt-out NASH, which makes diag-
nosis difficult.
NAFLD is the hepatic manifestation of metabolic syn-
drome accompanied by high rates of obesity, diabetes,
hyperlipidemia, and hypertension. As expected, patients
with cryptogenic HCC showed a higher prevalence of
metabolic syndrome than those with other HCCs, with
the highest mean age at diagnosis and lowest proportion
of male subjects compared to all other HCC groups. In
previous studies, patients with cryptogenic cirrhosis were
approximately 3 years older than patients with HCV at theTable 4 Comparison of visceral fat area and the liver-to-splee
carcinoma (HCC) patients and patients with HCC of other etio
§Cryptogenic
HCC (n = 18)
HBV-HCC
(n = 36)
Age (yr) † 70.3 ± 10.6 67.4 ± 9.1
Gender, male†† 9 (50.0) 9 (50.0)
BMI (kg/m2) † 24.7 ± 3.0 23.3 ± 3.1
VFA (cm2) † 134.4 ± 53.9 100.0 ± 51.3
Liver attenuation (HU) † 54.3 ± 5.5 53.7 ± 5.8
Spleen attenuation (HU) † 44.0 ± 4.5 43.7 ± 4.0
Liver/Spleen ratio† 1.24 ± 0.14 1.23 ± 0.14
†Expressed as the mean ± standard deviation. ††Expressed as the number of subjec
§ Available data in 18 patients. Eighteen patients with cryptogenic HCC were match
¶ Of 55 ALC-HCC, VFA was measured in 23 patients. ALC-HCC patients did not matc
were mostly of male gender and because the sample sizes of each subgroup were
HU, Hounsfield unit; VFA, Visceral fat accumulation; BMI, Body mass index.
*p: Cryptogenic HCC vs. HBV-HCC.
**p: Cryptogenic HCC vs. HCV-HCC.
***p: Cryptogenic HCC vs. ALC-HCC.time of HCC diagnosis [4,22], and the proportion of male
patients with NASH-associated cirrhosis was lower than
that of female patients. However, NAFLD-HCC showed
a modest male predominance, suggesting a higher car-
cinogenic potential in male patients [23,24].
Approximately 30% of patients did not realize that
they had HCC until symptomatic presentation, whereas
30% of cryptogenic HCC patients had their tumors
detected during surveillance. In a previous study, HCC
patients who were diagnosed through surveillance had
smaller tumors at diagnosis and were likely to be eligible
for surgical resection or RFA therapies, resulting in
survival improvement [6]. In our study, 9 patients with
cryptogenic HCC who were diagnosed during surveil-
lance had tumors less than 5 cm in diameter, with AFP
levels lower than 20 IU/mL (data not shown). Although
the cryptogenic HCC patients showed similarly elevated




**p ¶ ALC-HCC ***p
(n = 23)
0.201 69.0 ± 8.8 0.646 67.7 ± 9.6 0.510
1.000 9 (50.0) 1.000 18 (78.3) 0.097
0.196 22.8 ± 3.2 0.050 24.5 ± 4.9 0.415
0.037 105.0 ± 51.1 0.034 136.9 ± 64.9 0.599
0.533 53.5 ± 6.7 0.441 50.7 ± 8.3 0172
0.263 45.0 ± 3.8 0.734 44.0 ± 5.0 0.743
0.854 1.20 ± 0.14 0.419 1.15 ± 0.14 0.066
ts (%). Values in bold, statistically significant (p < 0.05).
ed for age and sex (1:2 ratio) with HBV-HCC or HCV-HCC patients.
h with regard to age and sex with cryptogenic-HCC patients because they
small.
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notransferase levels are within the normal range [25].
Therefore, further studies are needed to determine surveil-
lance indicators for cryptogenic HCC.
Approximately 25% of cryptogenic HCC patients in
this study did not show clinical or histological evidence
of cirrhosis, findings comparable with those of a cross-
sectional study in Japan where 43 of 87 patients histo-
logically proven to have NASH-associated HCC had no
established cirrhosis [24]. Since 2004, at least 116 cases
of biopsy-confirmed NAFLD-associated HCC without
cirrhosis have been reported, suggesting that non-cirrhotic
HCC may be a more common feature in NAFLD-
associated HCC than in viral- or ALC-HCC [26].
The clinical characteristics and disease course of crypto-
genic HCC was found to be more indolent than HCC
caused by viral or alcoholic liver disease. According to our
results, cryptogenic HCC presented as a solitary nodule
more frequently and with a significantly lower rate of
portal vein thrombosis than HBV-HCC, HCV-HCC, and
ALC-HCC. This is similar to the results of previous
studies, which documented that HCC nodules in patients
with NAFLD tended to be solitary lesions [27,28] or single,
large, or well-differentiated tumors [23,27,28], suggesting
that NAFLD-HCC has less severe tumor characteristics
than HCC caused by virus infection or alcohol. Single
nodular presentation may be related to a lower tendency
of portal vein invasion and, subsequently, less intrahepatic
metastasis. Additionally, no significant difference was
noted in Child Pugh classes, tumor stages, and overall
survival rates between the cryptogenic HCC patients
and the other HCC patients, a finding partially concordant
with other reports [29-31]. In recent studies, patients with
cryptogenic HCC had a higher survival rate than those
with HCV-HCC and/or ALC-HCC after curative treat-
ment [29,30]. This discrepancy may be related to the
patients’ characteristics of cryptogenic HCC, such as older
age and more frequent occurrence of metabolic syndrome
and other comorbidity, in spite of the less aggressive
behavior of tumors in cryptogenic HCC.
The most remarkable finding of the present study
was that VFA in cryptogenic HCC patients was higher
than that in either HBV-HCC or HCV-HCC patients,
whereas no significant difference was observed between
cryptogenic HCC and ALC-HCC patients. In contrast,
no difference was noted in the liver-to-spleen density
ratio according to HCC etiology. As previously reported,
the severity of fatty liver is positively correlated with
VFA, whereas VFA and the liver-spleen density ratio are
negatively correlated [9]. Moreover, the liver-to-spleen
density ratio tends to be lower in cirrhosis patients than in
non-cirrhotic NASH patients [10]. As hepatic fibrosis
progresses, the liver-to spleen density ratio may decrease
because liver fat storage is depleted, but visceral fat ispreserved. Therefore, our results suggest that cryptogenic
HCC may be associated with burnt-out NAFLD.
This study had several limitations because it was based
on a retrospective single-center design with a small
sample size. NAFLD was histologically proven only in 7
patients out of 35 with cryptogenic HCC. Body mass
index or alanine aminotransferase levels may fluctuate in
these patients during their lifetime, but retrospective na-
ture of this study could not show those clinical features.
Furthermore, in the context of occult HBV infection in
hepatocarcinogenesis, anti-HBc and HBV DNA were not
completely examined in all of the cryptogenic HCC
patients. In this study, 9 out of 35 cryptogenic HCC
patients showed anti-HBc positivity, but most of them
showed serum HBV DNA negativity, which may suggest
a trivial role for occult HBV infection in cryptogenic
HCC.
Conclusions
Cryptogenic HCC accounts for approximately 7% of
HCC cases in Korea and is associated with an older age
at diagnosis, high prevalence of metabolic syndrome,
and less aggressive tumor characteristics compared to
viral-HCC and ALC-HCC, but a similar overall survival
rate. VFA and the liver-spleen density ratio measure-
ments support the theory that most cryptogenic HCC
cases may be associated with burnt-out NAFLD. Surveil-
lance for the early detection of HCC in NAFLD patients
should be considered.
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